Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 33

1.

Long-term tolerability, immunogenicity and efficacy of Nuwiq® (human-cl rhFVIII) in children with severe haemophilia A.

Klukowska A, Szczepański T, Vdovin V, Knaub S, Bichler J, Jansen M, Dzhunova I, Liesner RJ.

Haemophilia. 2018 Mar 26. doi: 10.1111/hae.13460. [Epub ahead of print]

PMID:
29582516
2.

Pharmacokinetics, clot strength and safety of a new fibrinogen concentrate: randomized comparison with active control in congenital fibrinogen deficiency.

Ross C, Rangarajan S, Karimi M, Toogeh G, Apte S, Lissitchkov T, Acharya S, Manco-Johnson MJ, Srivastava A, Brand B, Schwartz BA, Knaub S, Peyvandi F.

J Thromb Haemost. 2018 Feb;16(2):253-261. doi: 10.1111/jth.13923. Epub 2018 Jan 22.

PMID:
29220876
3.

Efficacy and safety of a new human fibrinogen concentrate in patients with congenital fibrinogen deficiency: an interim analysis of a Phase III trial.

Lissitchkov T, Madan B, Djambas Khayat C, Zozulya N, Ross C, Karimi M, Kavakli K, De Angulo GR, Almomen A, Schwartz BA, Solomon C, Knaub S, Peyvandi F.

Transfusion. 2018 Feb;58(2):413-422. doi: 10.1111/trf.14421. Epub 2017 Nov 30.

PMID:
29194665
4.

Efficacy and safety of Nuwiq® (human-cl rhFVIII) in patients with severe haemophilia A undergoing surgical procedures.

Zozulya N, Kessler CM, Klukowska A, von Depka M, Hampton K, Hay CRM, Jansen M, Bichler J, Knaub S, Rangarajan S.

Haemophilia. 2018 Jan;24(1):70-76. doi: 10.1111/hae.13351. Epub 2017 Oct 19.

PMID:
29048712
5.

Immunogenicity, efficacy and safety of Nuwiq® (human-cl rhFVIII) in previously untreated patients with severe haemophilia A-Interim results from the NuProtect Study.

Liesner RJ, Abashidze M, Aleinikova O, Altisent C, Belletrutti MJ, Borel-Derlon A, Carcao M, Chambost H, Chan AKC, Dubey L, Ducore J, Fouzia NA, Gattens M, Gruel Y, Guillet B, Kavardakova N, El Khorassani M, Klukowska A, Lambert T, Lohade S, Sigaud M, Turea V, Wu JKM, Vdovin V, Pavlova A, Jansen M, Belyanskaya L, Walter O, Knaub S, Neufeld EJ.

Haemophilia. 2018 Mar;24(2):211-220. doi: 10.1111/hae.13320. Epub 2017 Aug 16.

PMID:
28815880
6.

PK-guided personalized prophylaxis with Nuwiq® (human-cl rhFVIII) in adults with severe haemophilia A.

Lissitchkov T, Rusen L, Georgiev P, Windyga J, Klamroth R, Gercheva L, Nemes L, Tiede A, Bichler J, Knaub S, Belyanskaya L, Walter O, Pasi KJ.

Haemophilia. 2017 Sep;23(5):697-704. doi: 10.1111/hae.13251. Epub 2017 Apr 27. Erratum in: Haemophilia. 2018 Jan;24(1):162.

PMID:
28452151
7.

Prophylaxis vs. on-demand treatment with Nuwiq(®) (Human-cl rhFVIII) in adults with severe haemophilia A.

Tiede A, Oldenburg J, Lissitchkov T, Knaub S, Bichler J, Manco-Johnson MJ.

Haemophilia. 2016 May;22(3):374-80. doi: 10.1111/hae.12859. Epub 2015 Nov 19.

PMID:
26582282
8.

Novel, human cell line-derived recombinant factor VIII (Human-cl rhFVIII, Nuwiq® ) in children with severe haemophilia A: efficacy, safety and pharmacokinetics.

Klukowska A, Szczepański T, Vdovin V, Knaub S, Jansen M, Liesner R.

Haemophilia. 2015 Sep 14. doi: 10.1111/hae.12797. [Epub ahead of print]

PMID:
26370328
9.

Novel, human cell line-derived recombinant factor VIII (human-cl rhFVIII; Nuwiq® ) in adults with severe haemophilia A: efficacy and safety.

Lissitchkov T, Hampton K, von Depka M, Hay C, Rangarajan S, Tuddenham E, Holstein K, Huth-Kühne A, Pabinger I, Knaub S, Bichler J, Oldenburg J.

Haemophilia. 2015 Aug 28. doi: 10.1111/hae.12793. [Epub ahead of print]

PMID:
26315974
10.

First prospective report on immune tolerance in poor risk haemophilia A inhibitor patients with a single factor VIII/von Willebrand factor concentrate in an observational immune tolerance induction study.

Kreuz W, Escuriola Ettingshausen C, Vdovin V, Zozulya N, Plyushch O, Svirin P, Andreeva T, Bubanská E, Campos M, Benedik-Dolničar M, Jiménez-Yuste V, Kitanovski L, Klukowska A, Momot A, Osmulskaya N, Prieto M, Šalek SZ, Velasco F, Pavlova A, Oldenburg J, Knaub S, Jansen M, Belyanskaya L, Walter O; ObsITI study group; ObsITI committee.

Haemophilia. 2016 Jan;22(1):87-95. doi: 10.1111/hae.12774. Epub 2015 Jul 23.

PMID:
26202305
11.

The first recombinant FVIII produced in human cells--an update on its clinical development programme.

Valentino LA, Negrier C, Kohla G, Tiede A, Liesner R, Hart D, Knaub S.

Haemophilia. 2014 Jan;20 Suppl 1:1-9. doi: 10.1111/hae.12322. Review.

PMID:
24330348
12.

The first recombinant human coagulation factor VIII of human origin: human cell line and manufacturing characteristics.

Casademunt E, Martinelle K, Jernberg M, Winge S, Tiemeyer M, Biesert L, Knaub S, Walter O, Schröder C.

Eur J Haematol. 2012 Aug;89(2):165-76. doi: 10.1111/j.1600-0609.2012.01804.x. Epub 2012 Jun 15.

13.

Use of objective efficacy criteria for evaluation of von Willebrand factor/factor VIII concentrates.

Kessler CM, Windyga J, Schwartz BA, Knaub S.

Blood Coagul Fibrinolysis. 2012 Jun;23(4):262-7. doi: 10.1097/MBC.0b013e3283504118.

PMID:
22322140
14.

A retrospective study of Octaplex in the treatment of bleeding in patients with haemophilia A complicated by inhibitors.

Berntorp E, Figueiredo S, Futema L, Pock K, Knaub S, Walter O, Trawnicek L, Römisch J.

Blood Coagul Fibrinolysis. 2010 Sep;21(6):577-83. doi: 10.1097/MBC.0b013e32833c9ab9.

PMID:
20644466
15.

Pharmacokinetics and safety of fibrinogen concentrate.

Manco-Johnson MJ, Dimichele D, Castaman G, Fremann S, Knaub S, Kalina U, Peyvandi F, Piseddu G, Mannucci P; FIBRINOGEN CONCENTRATE STUDY GROUP.

J Thromb Haemost. 2009 Dec;7(12):2064-9. doi: 10.1111/j.1538-7836.2009.03633.x. Epub 2009 Oct 5.

16.

Impact of infusion speed on the safety and effectiveness of prothrombin complex concentrate: a prospective clinical trial of emergency anticoagulation reversal.

Pabinger I, Tiede A, Kalina U, Knaub S, Germann R, Ostermann H; Beriplex P/N Anticoagulation Reversal Study Group.

Ann Hematol. 2010 Mar;89(3):309-16. doi: 10.1007/s00277-009-0830-7. Epub 2009 Sep 29.

PMID:
19787352
17.

Rotational thromboelastography for monitoring of fibrinogen concentrate therapy in fibrinogen deficiency.

Kalina U, Stöhr HA, Bickhard H, Knaub S, Siboni SM, Mannucci PM, Peyvandi F.

Blood Coagul Fibrinolysis. 2008 Dec;19(8):777-83. doi: 10.1097/MBC.0b013e32830ef90c.

PMID:
19002044
18.

A systematic overview of the first pasteurised VWF/FVIII medicinal product, Haemate P/ Humate -P: history and clinical performance.

Berntorp E, Archey W, Auerswald G, Federici AB, Franchini M, Knaub S, Kreuz W, Lethagen S, Mannucci PM, Pollmann H, Scharrer I, Hoots K.

Eur J Haematol Suppl. 2008 May;(70):3-35. doi: 10.1111/j.1600-0609.2008.01049.x. Review.

PMID:
18380871
19.

Prothrombin complex concentrate (Beriplex P/N) for emergency anticoagulation reversal: a prospective multinational clinical trial.

Pabinger I, Brenner B, Kalina U, Knaub S, Nagy A, Ostermann H; Beriplex P/N Anticoagulation Reversal Study Group.

J Thromb Haemost. 2008 Apr;6(4):622-31. doi: 10.1111/j.1538-7836.2008.02904.x. Epub 2008 Jan 15.

20.

Pharmacokinetics of Beriplex P/N prothrombin complex concentrate in healthy volunteers.

Ostermann H, Haertel S, Knaub S, Kalina U, Jung K, Pabinger I.

Thromb Haemost. 2007 Oct;98(4):790-7.

PMID:
17938803

Supplemental Content

Support Center